STAT+: Amgen combination treatment with KRAS-blocking drug shows improved response in colon cancer patients

A combination treatment that pairs Amgen’s KRAS-blocking drug with another of its targeted cancer medicines showed improved tumor response rates in patients with advanced colon cancer, the company said.

Click to view original post